Browsing Øvrige samlinger by Author "Førsund, Mette S"

Now showing items 1-3 of 3

  • Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma 
    Spasevska, Ivana; Sharma, Ankush; Steen, Chloe Beate; Josefsson, Sarah Elisabet; Blaker, Yngvild Nuvin; Kolstad, Arne; Rustad, Even Holth; Meyer, Saskia; Isaksen, Kathrine Thuestad; Chellappa, Stalin; Kushekhar, Kushi; Beiske, Klaus Hermann; Førsund, Mette S; Spetalen, Signe; Holte, Harald; Østenstad, Bjørn; Brodtkorb, Marianne; Kimby, Eva K; Olweus, Johanna; Tasken, Kjetil; Newman, Aron M; Lorenz, Susanne; Smeland, Erlend Bremertun; Alizadeh, Ash A.; Huse, Kanutte; Myklebust, June Helen (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
    Abstract Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin ...
  • Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro 
    Wang, Zhihui; Førsund, Mette S; Tropé, Claes Gøran; Nesland, Jahn M; Holm, Ruth; Slipicevic, Ana (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    CHK1 is an important regulator of the cell cycle and DNA damage response, and its altered expression has been identified in various tumors. Chk1 inhibitors are currently being evaluated as monotherapy and as potentiators ...
  • TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma 
    Josefsson, Sarah Elisabet; Beiske, Klaus; Blaker, Yngvild Nuvin; Førsund, Mette S; Holte, Harald; Østenstad, Bjørn; Kimby, Eva; Köksal, Hakan; Wälchli, Sébastien; Bai, Baoyan; Smeland, Erlend B; Levy, Ronald; Kolstad, Arne; Huse, Kanutte; Myklebust, June (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2019)
    Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma ...